DK2808393T3 - Cells insufficient for fucosylation - Google Patents

Cells insufficient for fucosylation Download PDF

Info

Publication number
DK2808393T3
DK2808393T3 DK14179885.0T DK14179885T DK2808393T3 DK 2808393 T3 DK2808393 T3 DK 2808393T3 DK 14179885 T DK14179885 T DK 14179885T DK 2808393 T3 DK2808393 T3 DK 2808393T3
Authority
DK
Denmark
Prior art keywords
cell
cells
fucosylation
fucose
val
Prior art date
Application number
DK14179885.0T
Other languages
Danish (da)
English (en)
Inventor
Gang Chen
Darya Burakov
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2808393T3 publication Critical patent/DK2808393T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271GDP-L-fucose synthase (1.1.1.271)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14179885.0T 2009-06-02 2010-06-01 Cells insufficient for fucosylation DK2808393T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27
EP10721096.5A EP2438171B1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (1)

Publication Number Publication Date
DK2808393T3 true DK2808393T3 (en) 2018-03-12

Family

ID=42338231

Family Applications (3)

Application Number Title Priority Date Filing Date
DK14179885.0T DK2808393T3 (en) 2009-06-02 2010-06-01 Cells insufficient for fucosylation
DK10721096.5T DK2438171T3 (en) 2009-06-02 2010-06-01 Fucosylerings-deficient cells
DK17192430.1T DK3279326T3 (da) 2009-06-02 2010-06-01 Fucosyleringsdeficiente celler

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10721096.5T DK2438171T3 (en) 2009-06-02 2010-06-01 Fucosylerings-deficient cells
DK17192430.1T DK3279326T3 (da) 2009-06-02 2010-06-01 Fucosyleringsdeficiente celler

Country Status (16)

Country Link
US (8) US8409838B2 (cg-RX-API-DMAC7.html)
EP (3) EP2438171B1 (cg-RX-API-DMAC7.html)
JP (4) JP5744856B2 (cg-RX-API-DMAC7.html)
KR (2) KR101441437B1 (cg-RX-API-DMAC7.html)
CN (1) CN102459603B (cg-RX-API-DMAC7.html)
AU (1) AU2010256753B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010035A2 (cg-RX-API-DMAC7.html)
CA (1) CA2764370C (cg-RX-API-DMAC7.html)
DK (3) DK2808393T3 (cg-RX-API-DMAC7.html)
ES (2) ES2661074T3 (cg-RX-API-DMAC7.html)
HU (1) HUE038596T2 (cg-RX-API-DMAC7.html)
IL (1) IL216624A (cg-RX-API-DMAC7.html)
PL (3) PL3279326T3 (cg-RX-API-DMAC7.html)
SG (1) SG176251A1 (cg-RX-API-DMAC7.html)
TW (1) TWI513818B (cg-RX-API-DMAC7.html)
WO (1) WO2010141478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US20160251410A1 (en) 2013-09-03 2016-09-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
MY178160A (en) 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
CN106604930B (zh) * 2014-05-30 2021-10-29 新英格兰生物实验室公司 去糖基化试剂和方法
CN114540266A (zh) * 2014-07-07 2022-05-27 塔尔加泽梅股份有限公司 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR102793554B1 (ko) 2015-11-02 2025-04-14 제넨테크, 인크. 단백질의 푸코실화 및 탈푸코실화 형태를 제조하는 방법
EP3400241B1 (en) 2016-01-06 2020-07-22 Outlook Therapeutics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP3445781A1 (en) 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
EA202092286A1 (ru) 2018-03-26 2021-03-18 Эмджен Инк. Общие афукозилированные гликоформы антител, полученные в культуре клеток
CA3110254C (en) * 2018-08-29 2023-08-29 United Biopharma Inc Afucosylated antibodies and manufacture thereof
US20220002389A1 (en) 2018-10-29 2022-01-06 Immuno-Biological Laboratories Co., Ltd. Anti-hiv antibody and method for producing same
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP2023527352A (ja) 2020-05-26 2023-06-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片
MX2022014852A (es) 2020-06-03 2023-02-01 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov-2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2.
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4359440A1 (en) 2021-06-22 2024-05-01 Regeneron Pharmaceuticals, Inc. Anti-egfrviii antibody drug conjugates and uses thereof
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
KR20240167714A (ko) 2022-03-02 2024-11-27 리제너론 파아마슈티컬스, 인크. 고역가 항체의 제조 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
EP2278003B2 (en) * 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
CA2434802C (en) 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
JP2005532253A (ja) 2001-10-25 2005-10-27 ジェネンテック・インコーポレーテッド 糖タンパク質組成物
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
SI2059536T1 (sl) 2006-08-14 2014-06-30 Xencor, Inc. Optimirana protitelesa, ki ciljajo CD19
KR20090130029A (ko) 2007-03-07 2009-12-17 글리코파이, 인크. 푸코실화가 변형된 당단백질의 제조
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2010018847A1 (ja) 2008-08-13 2010-02-18 協和発酵キリン株式会社 遺伝子組換えプロテインs組成物
US8409838B2 (en) 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
CN103597073B (zh) 2011-03-06 2019-06-07 默克雪兰诺有限公司 低岩藻糖细胞系及其应用

Also Published As

Publication number Publication date
US20230295583A1 (en) 2023-09-21
US20190024129A1 (en) 2019-01-24
EP2808393A2 (en) 2014-12-03
JP2017006147A (ja) 2017-01-12
SG176251A1 (en) 2011-12-29
US8409838B2 (en) 2013-04-02
JP2016104045A (ja) 2016-06-09
US20160090410A1 (en) 2016-03-31
HUE038596T2 (hu) 2018-10-29
IL216624A0 (en) 2012-02-29
IL216624A (en) 2015-02-26
BRPI1010035A2 (pt) 2015-08-25
CA2764370A1 (en) 2010-12-09
US9550823B2 (en) 2017-01-24
US20100304436A1 (en) 2010-12-02
HK1198180A1 (en) 2015-03-13
US12054751B2 (en) 2024-08-06
EP2808393B1 (en) 2018-01-10
US20210254022A1 (en) 2021-08-19
KR20120029443A (ko) 2012-03-26
AU2010256753A1 (en) 2012-01-12
EP2438171B1 (en) 2014-12-17
TW201107469A (en) 2011-03-01
PL2808393T3 (pl) 2018-04-30
CA2764370C (en) 2018-08-21
US20200080124A1 (en) 2020-03-12
JP6211642B2 (ja) 2017-10-11
EP3279326B1 (en) 2020-10-14
JP2012528594A (ja) 2012-11-15
CN102459603B (zh) 2013-11-06
KR101441437B1 (ko) 2014-09-25
PL2438171T3 (pl) 2015-04-30
JP2015051021A (ja) 2015-03-19
US9206455B2 (en) 2015-12-08
AU2010256753B2 (en) 2013-11-28
ES2527173T3 (es) 2015-01-21
DK2438171T3 (en) 2015-01-26
ES2661074T3 (es) 2018-03-27
KR101641526B1 (ko) 2016-07-21
TWI513818B (zh) 2015-12-21
JP5744856B2 (ja) 2015-07-08
EP3279326A1 (en) 2018-02-07
HK1163745A1 (en) 2012-09-14
KR20140039340A (ko) 2014-04-01
CN102459603A (zh) 2012-05-16
US20170211115A1 (en) 2017-07-27
EP2808393A3 (en) 2015-03-11
EP2438171A1 (en) 2012-04-11
PL3279326T3 (pl) 2021-03-08
DK3279326T3 (da) 2020-12-21
HK1249547A1 (en) 2018-11-02
US10006070B2 (en) 2018-06-26
US11560550B2 (en) 2023-01-24
US20130164786A1 (en) 2013-06-27
WO2010141478A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
US12054751B2 (en) Fucosylation-deficient cells
AU2015282354B2 (en) Fucosylation-deficient cells
AU2012100020A6 (en) Fucosylation-deficient cells
AU2014200152B2 (en) Fucosylation-deficient cells
HK1249547B (en) Fucosylation-deficient cells
HK1198180B (en) Fucosylation-deficient cells
HK1163745B (en) Fucosylation-deficient cells